Attention-deficit/hyperactivity disorder (ADHD) diagnosis for children and adults has increased worldwide, particularly in North America. Both diagnostic rates and stimulant prescribing rates have increased as ADHD has gained national and international attention in the news and social media.
Diagnosing ADHD is complicated and can take time and effort. CPSBC is reminding registrants to follow best practice guidelines to improve patient outcomes and avoid harm.
CPSBC recognizes prescribing opioids, sedatives, antimicrobials and stimulants can cause potential harm to patients. There are risks to consider when prescribing stimulants for ADHD, including:
- patients' overvaluation of their benefits
- potential for dependence and addiction
- diversion of these drugs for non-medical use
- their popularity in popular culture and social media
While CPSBC cannot address these risks directly as a regulator, it has a duty to advise registrants to navigate these issues cautiously to reduce the potential harm to patients and the public.
Treating ADHD in children and adults can become part of a registrant's competent scope of practice. All registrants must be able to address their patients' concerns, even if it is beyond their scope to diagnose and treat ADHD. This includes simply offering advice on where to seek help.
CPSBC has published information on ADHD prescribing on its website and encourages registrants to learn more about this emerging issue and the ongoing scientific research.